3a,4,5,6,7,7a-hexahydro-1H-benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 3a,4,5,6,7,7a-hexahydro-1H-benzimidazole
• 化学式: C₇H₁₂N₂
• mdl: MFCD07778362
• 分子量: 124.18
• InChiKey: UKIALOXIKPBHPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3a,4,5,6,7,7a-hexahydro-1H-benzimidazole 、 异氰酸苯酯 以85%的产率得到
  参考文献：
  名称：

  GIESECKE H.; HOCKER J., SYNTHESIS, 1977, NO 11, 806-808

  摘要：

  DOI：
• 作为产物：
  描述：

  N'-(2-bromocyclohexyl)methanimidamide;hydrochloride 、 氢氧化钾 生成 3a,4,5,6,7,7a-hexahydro-1H-benzimidazole
  参考文献：
  名称：

  JUNG, SANG-HUN;KOHN, H., TETRAHEDRON LETT., 1984, 25, N 4, 399-402

  摘要：

  DOI：

文献信息

• Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings
  申请人：Allergan, Inc.

  公开号：US20160289271A1

  公开（公告）日：2016-10-06

  The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.

  本发明涉及新型环孢素类似物，制备它们的方法，含有它们的药物组合物，以及利用这些类似物和含有它们的组合物治疗医疗状况的方法，包括但不限于眼部状况如干眼症。
• COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF
  申请人：Hanada Keisuke

  公开号：US20090325992A1

  公开（公告）日：2009-12-31

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  化合物的一般式（I）所代表的化合物，其盐、溶剂化物或前药，其中所有符号均如规范中定义的那样，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、精神神经疾病、脑部疾病、心血管疾病、代谢性疾病、癌症（例如癌症、癌症转移等）的预防和/或治疗药物，或作为再生疗法的药物。
• CDK KINASE INHIBITOR
  申请人：Beijing Benicall Biotech Co., Ltd.

  公开号：EP3988551A1

  公开（公告）日：2022-04-27

  Disclosed in the present application are a compound of general formula (I) capable of being used as a CDK kinase (in particular, CDK4/6 kinase) inhibitor, and a salt thereof, wherein all variates are defined as the present text. The compound can be used for treating or preventing diseases such as cancer. The present application further relates to a pharmaceutical composition comprising the compound of formula (I).

  本申请公开了一种可用作 CDK 激酶（尤其是 CDK4/6 激酶）抑制剂的通式（I）化合物及其盐，其中所有变体的定义与本文相同。该化合物可用于治疗或预防癌症等疾病。本申请进一步涉及一种包含式（I）化合物的药物组合物。
• Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
  申请人：Allergan, Inc.

  公开号：US10077289B2

  公开（公告）日：2018-09-18

  The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.

  本发明涉及新型环孢素类似物、制备环孢素类似物的工艺、含有环孢素类似物的药物组合物，以及使用这些类似物和含有环孢素类似物的组合物治疗疾病（包括但不限于干眼症等眼部疾病）的方法。
• Compositions for the treatment of pulmonary fibrosis
  申请人：Vectus Biosystems Limited

  公开号：US10919863B2

  公开（公告）日：2021-02-16

  The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

  本发明涉及化合物及其在肺纤维化和/或相关疾病的预防和/或治疗中的用途。